PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-21.43%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-42.33%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
111.92%
Positive EBIT growth while CSIQ is negative. John Neff might see a substantial edge in operational management.
64.58%
Positive operating income growth while CSIQ is negative. John Neff might view this as a competitive edge in operations.
1454.16%
Positive net income growth while CSIQ is negative. John Neff might see a big relative performance advantage.
1511.76%
Positive EPS growth while CSIQ is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
1581.48%
Positive diluted EPS growth while CSIQ is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.70%
Slight or no buybacks while CSIQ is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
8.33%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
111.51%
OCF growth of 111.51% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
107.53%
FCF growth of 107.53% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
-48.37%
Negative 10Y revenue/share CAGR while CSIQ stands at 52.77%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-26.79%
Negative 5Y CAGR while CSIQ stands at 2.70%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-11.74%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
117.10%
OCF/share CAGR of 117.10% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
107.70%
OCF/share CAGR of 107.70% while CSIQ is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
110.47%
3Y OCF/share CAGR of 110.47% while CSIQ is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
275.24%
Net income/share CAGR at 75-90% of CSIQ's 362.00%. Bill Ackman would press for strategic moves to boost long-term earnings.
135.32%
5Y net income/share CAGR above 1.5x CSIQ's 8.39%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
116.95%
Positive short-term CAGR while CSIQ is negative. John Neff would see a clear advantage in near-term profit trajectory.
-98.79%
Negative equity/share CAGR over 10 years while CSIQ stands at 128.96%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-98.37%
Negative 5Y equity/share growth while CSIQ is at 80.99%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-96.52%
Negative 3Y equity/share growth while CSIQ is at 58.79%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.94%
Firm’s AR is declining while CSIQ shows 8.05%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-8.01%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-2.95%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
104.47%
BV/share growth above 1.5x CSIQ's 3.75%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.32%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-21.12%
Our R&D shrinks while CSIQ invests at 8.63%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.15%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.